JPWO2020132560A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132560A5 JPWO2020132560A5 JP2021536007A JP2021536007A JPWO2020132560A5 JP WO2020132560 A5 JPWO2020132560 A5 JP WO2020132560A5 JP 2021536007 A JP2021536007 A JP 2021536007A JP 2021536007 A JP2021536007 A JP 2021536007A JP WO2020132560 A5 JPWO2020132560 A5 JP WO2020132560A5
- Authority
- JP
- Japan
- Prior art keywords
- tdsrna
- checkpoint inhibitor
- use according
- checkpoint
- rin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 68
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 68
- 239000000203 mixture Substances 0.000 claims 15
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 13
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 10
- 229960001592 Paclitaxel Drugs 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 230000002195 synergetic Effects 0.000 claims 8
- 230000003442 weekly Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- 102100007290 CD274 Human genes 0.000 claims 6
- 101710012053 CD274 Proteins 0.000 claims 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 6
- 229960002949 Fluorouracil Drugs 0.000 claims 6
- 108060004270 LAG3 Proteins 0.000 claims 6
- 102100017213 LAG3 Human genes 0.000 claims 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 229960004316 cisplatin Drugs 0.000 claims 6
- 229930003347 taxol Natural products 0.000 claims 6
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 102100009333 BTLA Human genes 0.000 claims 4
- 101700047069 BTLA Proteins 0.000 claims 4
- 102100019451 CD80 Human genes 0.000 claims 4
- 101700080477 CD80 Proteins 0.000 claims 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 229960004562 Carboplatin Drugs 0.000 claims 4
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 4
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 4
- 229960004397 Cyclophosphamide Drugs 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- 229960003957 Dexamethasone Drugs 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 4
- 229960004679 Doxorubicin Drugs 0.000 claims 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 4
- 101710004393 HAVCR2 Proteins 0.000 claims 4
- 102100016384 HAVCR2 Human genes 0.000 claims 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 4
- 229960001101 Ifosfamide Drugs 0.000 claims 4
- 102000002698 KIR Receptors Human genes 0.000 claims 4
- 108010043610 KIR Receptors Proteins 0.000 claims 4
- 102100006047 TIGIT Human genes 0.000 claims 4
- 101700052319 TIGIT Proteins 0.000 claims 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 claims 3
- 108010090838 Alemtuzumab Proteins 0.000 claims 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 3
- 108010092160 Dactinomycin Proteins 0.000 claims 3
- 229960000640 Dactinomycin Drugs 0.000 claims 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 108020004461 Double-Stranded RNA Proteins 0.000 claims 3
- 229960001904 EPIRUBICIN Drugs 0.000 claims 3
- 108010089187 Ipilimumab Proteins 0.000 claims 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 3
- 108010019706 Nivolumab Proteins 0.000 claims 3
- 229960002450 Ofatumumab Drugs 0.000 claims 3
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 claims 3
- 108010001645 Rituximab Proteins 0.000 claims 3
- 229960001052 Streptozocin Drugs 0.000 claims 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 3
- 229960004528 Vincristine Drugs 0.000 claims 3
- NMDYYWFGPIMTKO-HBVLKOHWSA-N Vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 claims 3
- 229960000548 alemtuzumab Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960003603 decitabine Drugs 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 3
- 229960005386 ipilimumab Drugs 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 229960001924 melphalan Drugs 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 108010052070 ofatumumab Proteins 0.000 claims 3
- 108010026276 pembrolizumab Proteins 0.000 claims 3
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 230000004083 survival Effects 0.000 claims 3
- 230000001225 therapeutic Effects 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- 229960000922 vinflunine Drugs 0.000 claims 3
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims 2
- MUVQOOPKPBEAJZ-VQHVLOKHSA-N (4E)-4-[(3-chloro-4-fluoroanilino)-nitrosomethylidene]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Cl)=C1 MUVQOOPKPBEAJZ-VQHVLOKHSA-N 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 2
- 229940028652 Abraxane Drugs 0.000 claims 2
- 229940098174 Alkeran Drugs 0.000 claims 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 2
- 229950002916 Avelumab Drugs 0.000 claims 2
- 229960002756 Azacitidine Drugs 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 108010090685 BMS-936559 Proteins 0.000 claims 2
- 229940083476 Bosulif Drugs 0.000 claims 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N Bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 2
- 102100013137 CD40 Human genes 0.000 claims 2
- 101710040446 CD40 Proteins 0.000 claims 2
- 102100013078 CD47 Human genes 0.000 claims 2
- 101700033237 CD47 Proteins 0.000 claims 2
- 102100019283 CD52 Human genes 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102100005830 CD70 Human genes 0.000 claims 2
- 101700017377 CD70 Proteins 0.000 claims 2
- 229960004117 Capecitabine Drugs 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 2
- 229940088547 Cosmegen Drugs 0.000 claims 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- 229940059359 Dacogen Drugs 0.000 claims 2
- 229960002272 Degarelix Drugs 0.000 claims 2
- MEUCPCLKGZSHTA-XYAYPHGZSA-N Degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims 2
- 229950009791 Durvalumab Drugs 0.000 claims 2
- 229940047887 Etopophos Drugs 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 2
- 229960002258 Fulvestrant Drugs 0.000 claims 2
- 229950001109 Galiximab Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 claims 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 claims 2
- 108010093641 IPH-2101 Proteins 0.000 claims 2
- 229960000908 Idarubicin Drugs 0.000 claims 2
- 229960003445 Idelalisib Drugs 0.000 claims 2
- YKLIKGKUANLGSB-HNNXBMFYSA-N Idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 2
- 229950009034 Indoximod Drugs 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229940089787 KADCYLA Drugs 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 2
- 102100016650 LAIR1 Human genes 0.000 claims 2
- 101700010670 LAIR1 Proteins 0.000 claims 2
- 102100016649 LAIR2 Human genes 0.000 claims 2
- 101700035069 LAIR2 Proteins 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- 229940063725 Leukeran Drugs 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229940090004 Megace Drugs 0.000 claims 2
- 229950007699 Mogamulizumab Drugs 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N Olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 2
- 102100007289 PDCD1LG2 Human genes 0.000 claims 2
- 101710011976 PDCD1LG2 Proteins 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 2
- 108010039918 Polylysine Proteins 0.000 claims 2
- 102100004476 SIRPA Human genes 0.000 claims 2
- 101710024246 SIRPA Proteins 0.000 claims 2
- 229940063683 Taxotere Drugs 0.000 claims 2
- 108010010691 Trastuzumab Proteins 0.000 claims 2
- 229950007217 Tremelimumab Drugs 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- 229950005972 Urelumab Drugs 0.000 claims 2
- 102100015314 VSIR Human genes 0.000 claims 2
- 101710036075 VSIR Proteins 0.000 claims 2
- 101700068327 VTCN1 Proteins 0.000 claims 2
- 102100014952 VTCN1 Human genes 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- 229960004355 Vindesine Drugs 0.000 claims 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 2
- 229940053890 Zanosar Drugs 0.000 claims 2
- 229940051084 Zytiga Drugs 0.000 claims 2
- 229960004103 abiraterone acetate Drugs 0.000 claims 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000000996 additive Effects 0.000 claims 2
- 108010072668 atezolizumab Proteins 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 108010010826 avelumab Proteins 0.000 claims 2
- 229960003005 axitinib Drugs 0.000 claims 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 2
- 229960003736 bosutinib Drugs 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229960002436 cladribine Drugs 0.000 claims 2
- 229960000928 clofarabine Drugs 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 229960005061 crizotinib Drugs 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- 108010016436 durvalumab Proteins 0.000 claims 2
- 229960000752 etoposide phosphate Drugs 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- 229960005304 fludarabine phosphate Drugs 0.000 claims 2
- 102000037240 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 108010012206 galiximab Proteins 0.000 claims 2
- 229960001330 hydroxycarbamide Drugs 0.000 claims 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 claims 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 2
- URXWVWVPMJSAJD-KOORYGTMSA-N megestrol acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 URXWVWVPMJSAJD-KOORYGTMSA-N 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 229960001428 mercaptopurine Drugs 0.000 claims 2
- 108010007997 mogamulizumab Proteins 0.000 claims 2
- 229960000572 olaparib Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims 2
- 108010011110 polyarginine Proteins 0.000 claims 2
- 229920000656 polylysine Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229960004836 regorafenib Drugs 0.000 claims 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 230000000087 stabilizing Effects 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims 2
- 229960000977 trabectedin Drugs 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 108010072993 tremelimumab Proteins 0.000 claims 2
- 210000004881 tumor cells Anatomy 0.000 claims 2
- 108010053952 urelumab Proteins 0.000 claims 2
- 229960000241 vandetanib Drugs 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N Abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 1
- 229940019829 Abstral Drugs 0.000 claims 1
- 229940060201 Actiq Drugs 0.000 claims 1
- 229940035938 Adcetris Drugs 0.000 claims 1
- 108010026410 Ado-Trastuzumab Emtansine Proteins 0.000 claims 1
- 229940009456 Adriamycin Drugs 0.000 claims 1
- 229940042992 Afinitor Drugs 0.000 claims 1
- 229960001220 Amsacrine Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 229940110584 Arzerra Drugs 0.000 claims 1
- 229940120638 Avastin Drugs 0.000 claims 1
- FUKOGSUFTZDYOI-BMANNDLBSA-O BEACOPP protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C FUKOGSUFTZDYOI-BMANNDLBSA-O 0.000 claims 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 108010005144 Bevacizumab Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 108010037003 Buserelin Proteins 0.000 claims 1
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 claims 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 claims 1
- 102100003755 CCNO Human genes 0.000 claims 1
- 101700047412 CCNO Proteins 0.000 claims 1
- 102100006435 CSF3 Human genes 0.000 claims 1
- PGMBSCDPACPRSG-SCSDYSBLSA-N Capiri Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PGMBSCDPACPRSG-SCSDYSBLSA-N 0.000 claims 1
- 229940056434 Caprelsa Drugs 0.000 claims 1
- 230000036536 Cave Effects 0.000 claims 1
- 108010022830 Cetuximab Proteins 0.000 claims 1
- JCYRRZITSZDHKN-WODMUGMNSA-N ChlVPP protocol Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1.OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JCYRRZITSZDHKN-WODMUGMNSA-N 0.000 claims 1
- 229960004630 Chlorambucil Drugs 0.000 claims 1
- ZCZQDTUCMRSEAS-CCLYOLAMSA-N Co-codamol Chemical compound OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZCZQDTUCMRSEAS-CCLYOLAMSA-N 0.000 claims 1
- 229950006799 Crisantaspase Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 Daunorubicin Drugs 0.000 claims 1
- 108010043242 Denosumab Proteins 0.000 claims 1
- GNGACRATGGDKBX-UHFFFAOYSA-N Dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims 1
- 229940115080 Doxil Drugs 0.000 claims 1
- 229940120655 Eloxatin Drugs 0.000 claims 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N Enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 1
- 229940082789 Erbitux Drugs 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- 229940087861 Faslodex Drugs 0.000 claims 1
- 229940087476 Femara Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229940002006 Firmagon Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229940020967 Gemzar Drugs 0.000 claims 1
- 229940084910 Gliadel Drugs 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 229940022353 Herceptin Drugs 0.000 claims 1
- 229940096120 Hydrea Drugs 0.000 claims 1
- 102100008778 IFNA10 Human genes 0.000 claims 1
- 101710024928 IFNA10 Proteins 0.000 claims 1
- 102100008781 IFNA16 Human genes 0.000 claims 1
- 101710024930 IFNA16 Proteins 0.000 claims 1
- 102100008780 IFNA17 Human genes 0.000 claims 1
- 101710024946 IFNA17 Proteins 0.000 claims 1
- 102100014278 IFNA4 Human genes 0.000 claims 1
- 101700024654 IFNA4 Proteins 0.000 claims 1
- 102100014274 IFNA7 Human genes 0.000 claims 1
- 101700071781 IFNA7 Proteins 0.000 claims 1
- 102100014275 IFNA8 Human genes 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229940005319 Inlyta Drugs 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 229940084651 Iressa Drugs 0.000 claims 1
- 229940025735 Jevtana Drugs 0.000 claims 1
- 229940022039 Keytruda Drugs 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 210000000265 Leukocytes Anatomy 0.000 claims 1
- 108010000817 Leuprolide Proteins 0.000 claims 1
- 229960004338 Leuprorelin Drugs 0.000 claims 1
- 229940100352 Lynparza Drugs 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 229960004296 Megestrol Acetate Drugs 0.000 claims 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 229940090009 Myleran Drugs 0.000 claims 1
- 229940086322 Navelbine Drugs 0.000 claims 1
- 229940080607 Nexavar Drugs 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 229940109551 Nipent Drugs 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 229960002700 Octreotide Drugs 0.000 claims 1
- 108010016076 Octreotide Proteins 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 claims 1
- 229960002340 Pentostatin Drugs 0.000 claims 1
- 229940039551 Perjeta Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229940092597 Prolia Drugs 0.000 claims 1
- 229940063222 Provera Drugs 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960004622 Raloxifene Drugs 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 229940120975 Revlimid Drugs 0.000 claims 1
- 229940078986 Somatuline Drugs 0.000 claims 1
- 229940090374 Stivarga Drugs 0.000 claims 1
- 229940081616 Tafinlar Drugs 0.000 claims 1
- 229940099419 Targretin Drugs 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- 229940069905 Tasigna Drugs 0.000 claims 1
- 229960003433 Thalidomide Drugs 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N Tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- 229940065658 Vidaza Drugs 0.000 claims 1
- 229940049068 Xalkori Drugs 0.000 claims 1
- 229940014556 Xgeva Drugs 0.000 claims 1
- 229940055760 Yervoy Drugs 0.000 claims 1
- 229940004212 Yondelis Drugs 0.000 claims 1
- 229940036061 Zaltrap Drugs 0.000 claims 1
- 229940034727 Zelboraf Drugs 0.000 claims 1
- 229940095188 Zydelig Drugs 0.000 claims 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N [(2R)-3-[2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethoxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexad Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 claims 1
- YCPOZVAOBBQLRI-PHDIDXHHSA-N [(2R,3R)-2,3-dihydroxy-4-methylsulfonyloxybutyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-PHDIDXHHSA-N 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- 229960000853 abiraterone Drugs 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 229960002719 buserelin Drugs 0.000 claims 1
- 229960001573 cabazitaxel Drugs 0.000 claims 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 230000003111 delayed Effects 0.000 claims 1
- 230000036425 denaturation Effects 0.000 claims 1
- 238000004925 denaturation Methods 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 229960004671 enzalutamide Drugs 0.000 claims 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 claims 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002074 flutamide Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 229940027318 hydroxyurea Drugs 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108010047126 interferon-alpha 8 Proteins 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 229960002437 lanreotide Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229960005225 mifamurtide Drugs 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229930014694 morphine Natural products 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- 108010045555 obinutuzumab Proteins 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
- 229960003181 treosulfan Drugs 0.000 claims 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims 1
- CILBMBUYJCWATM-IJDPFCGHSA-N vinorelbine L-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-IJDPFCGHSA-N 0.000 claims 1
Claims (52)
対象へと、少なくとも第1の化合物および第2の化合物を、任意の順序において、併せて、または個別に投与すること
を含み、
第1の化合物が、少なくとも1つの薬学的に許容可能な担体を伴ってもよい、有効量のチェックポイント阻害剤を含み、
第2の化合物が、少なくとも1つの薬学的に許容可能な担体を伴ってもよい、有効量の治療用二本鎖RNA(tdsRNA)である、方法。 A method for treating cancer in a subject in need of cancer treatment, comprising:
administering to the subject at least the first compound and the second compound in any order, jointly or separately;
the first compound comprises an effective amount of a checkpoint inhibitor optionally associated with at least one pharmaceutically acceptable carrier;
The method wherein the second compound is an effective amount of a therapeutic double-stranded RNA (tdsRNA) optionally associated with at least one pharmaceutically acceptable carrier.
全dsRNAのうちの少なくとも40重量パーセントが、直鎖状構造であるか;
全dsRNAのうちの少なくとも50重量パーセントが、直鎖状構造であるか;
全dsRNAのうちの少なくとも60重量パーセントが、直鎖状構造であるか;
全dsRNAのうちの少なくとも70重量パーセントが、直鎖状構造であるか;
全dsRNAのうちの少なくとも80重量パーセントが、直鎖状構造であるか;または
全dsRNAのうちの少なくとも90重量パーセントが、直鎖状構造である、tdsRNAを含む、請求項1から10のいずれかに記載の方法、または請求項1から10のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 the second compound has at least 30 weight percent of the total dsRNA in a linear structure;
at least 40 percent by weight of the total dsRNA is a linear structure;
at least 50 weight percent of the total dsRNA is a linear structure;
at least 60 weight percent of the total dsRNA is linear;
at least 70 weight percent of the total dsRNA is a linear structure;
11. Any of claims 1-10, comprising a tdsRNA wherein at least 80 weight percent of the total dsRNA is linear; or at least 90 weight percent of the total dsRNA is linear. or a checkpoint inhibitor and a tdsRNA for use according to any one of claims 1-10.
1重量パーセント;5重量パーセント;10重量パーセント;20重量パーセント;30重量パーセント;40重量パーセント;50重量パーセント;60重量パーセント;70重量パーセント;80重量パーセント;および90重量パーセント
からなる群から選択される値を超える、全RNAのうちの重量パーセントを有する、請求項1から13のいずれかに記載の方法、または請求項1から13のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 tdsRNA is
10 weight percent; 20 weight percent; 30 weight percent; 40 weight percent; 50 weight percent; 14. A method according to any one of claims 1 to 13, or a checkpoint inhibitor and tdsRNA for use according to any one of claims 1 to 13, having a weight percent of total RNA exceeding the value of .
rIn・r(C11-14U)n;rIn・r(C4U)n;rIn・r(C5U)n;rIn・r(C6U)n;rIn・r・r(C10U)n;rIn・r(C11U)n;rIn・r(C13U)n;rIn・r(C14U)n;rIn・r(C15U)n;rIn・r(C16U)n;rIn・r(C17U)n;rIn・r(C18U)n;rIn・r(C19U)n;rIn・r(C20U)n;rIn・r(C21U)n;rIn・r(C22U)n;rIn・r(C23U)n;rIn・r(C24U)n;rIn・r(C25U)n;rIn・r(C26U)n;rIn・r(C27U)n;rIn・r(C28U)n;rIn・r(C29U)n;rIn・r(C30U)n;rIn・r(C31U)n;rIn・r(C32U)n;rIn・r(C33U)n;rIn・r(C34U)n;rIn・r(C35U)n;rIn・r(C4-30U)n;rIn・r(C14-30U)n;rIn・r(C11-14G)n;rIn・r(C4-29G)n;rIn・r(C30-35U)n;r(ポリI・ポリC)n;r(ポリA・ポリU)n
からなる群から選択され;
nが、
40~50,000;50~10,000;60~9000;70~8000;80~7000;および380~450
からなる群から選択される整数である、請求項1から14のいずれかに記載の方法、または請求項1から14のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 tdsRNA is
rI n・r(C 11-14 U) n ;rI n・r(C 4 U) n ;rI n・r(C 5 U) n ;rI n・r(C 6 U) n ;rI n・r r ( C10U ) n ; rIn.r ( C11U ) n ; rIn.r ( C13U) n ; rIn.r ( C14U) n ; rIn.r ( C15U ) n ; rIn.r ( C16U ) n ; rIn.r ( C17U ) n ; rIn.r ( C18U )n ; r ( C20U ) n ; rIn.r ( C21U ) n ;rIn.r ( C22U) n ;rIn.r ( C23U) n ;rIn.r ( C24U ) rIn.r( C25U ) n ; rIn.r (C26U)n ; rIn.r ( C27U ) n ; rIn.r ( C28U ) n ; ( C29U ) n ;rIn.r( C30U ) n ;rIn.r ( C31U ) n ;rIn.r ( C32U ) n ;rIn.r ( C33U ) n rI n.r(C 34 U) n ;rI n.r (C 35 U) n ;rI n.r ( C.sub.4-30 U) n ;rI n.r (C.sub.14-30 U) n ; rI n・r(C 11-14 G) n ;rI n・r(C 4-29 G) n ;rI n・r(C 30-35 U) n ;r(poly I・poly C) n ;r( Poly A/Poly U) n
selected from the group consisting of;
n is
40-50,000; 50-10,000; 60-9000; 70-8000; 80-7000; and 380-450
15. A method according to any one of claims 1 to 14, or a checkpoint inhibitor and a tdsRNA for use according to any one of claims 1 to 14, which is an integer selected from the group consisting of:
対象の生存の延長;
対象の進行時間の延長;
腫瘍増殖の阻害;
腫瘍細胞死の誘導;
腫瘍退縮の増大;
腫瘍再発の防止;
腫瘍増殖の防止;
腫瘍拡大の防止;
腫瘍再発の遅延;
腫瘍増殖の遅延;
腫瘍拡大の遅延;および
腫瘍消失の促進
からなる群から選択される、請求項17もしくは18に記載の方法、または請求項17もしくは18に記載の使用のためのチェックポイント阻害剤およびtdsRNA。 The synergistic effect
prolonging survival of a subject;
Increased progression time for the subject;
inhibition of tumor growth;
induction of tumor cell death;
increased tumor regression;
prevention of tumor recurrence;
prevention of tumor growth;
prevention of tumor spread;
delayed tumor recurrence;
slowing tumor growth;
19. A method according to claim 17 or 18, or a checkpoint inhibitor and a tdsRNA for use according to claim 17 or 18, selected from the group consisting of delaying tumor expansion; and promoting tumor disappearance.
化学療法薬;
標的化された抗がん薬;および
抗体を含む標的化された抗がん薬
からなる群から選択される1つまたは複数である、請求項1から21のいずれかに記載の方法、または請求項1から21のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 further comprising administering to the subject a third compound, wherein the third compound is
chemotherapy drugs;
a targeted anticancer drug; and a targeted anticancer drug comprising an antibody. A checkpoint inhibitor and tdsRNA for use according to any of paragraphs 1-21.
tdsRNAおよびチェックポイント阻害剤と相乗的であるか、
治療有効量であるか、またはこれらの両方
である、請求項22に記載の方法、または請求項22に記載の使用のためのチェックポイント阻害剤およびtdsRNA。 An effective amount of the third compound is
synergistic with tdsRNA and checkpoint inhibitors;
23. The method of claim 22, or the checkpoint inhibitor and tdsRNA for use according to claim 22, in therapeutically effective amounts, or both.
インターフェロン;
インターフェロン混合物;
Alferon;および
アルファ-インターフェロン分子種
からなる群から選択される1つまたは複数を投与することをさらに含む、請求項1から23のいずれかに記載の方法、または請求項1から23のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 to the target
interferon;
interferon mixture;
24. The method of any of claims 1-23, or any of claims 1-23, further comprising administering one or more selected from the group consisting of: Alferon; Checkpoint inhibitors and tdsRNAs for the uses described.
tdsRNAが、毎月1回、3週間ごとに1回、2週間ごとに1回、毎週1回、毎週2回、毎週3回、毎週4回、毎週5回、毎週6回、および毎日からなる群から選択される頻度において投与される、請求項1から28のいずれかに記載の方法、または請求項1から28のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 the tdsRNA and the checkpoint inhibitor are administered separately at different time intervals;
Groups where the tdsRNA consisted of once monthly, once every three weeks, once every two weeks, once weekly, twice weekly, three times weekly, four times weekly, five times weekly, six times weekly, and daily. 29. The method of any of claims 1-28, or the checkpoint inhibitor and tdsRNA for use according to any of claims 1-28, administered at a frequency selected from:
2カ月間;1カ月間;3週間;2週間;1週間;3日間;1日間;12時間、6時間、3時間、2時間、1時間、および30分間
からなる群から選択される時間以内に投与される、請求項1から29のいずれかに記載の方法、または請求項1から29のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 The tdsRNA and checkpoint inhibitor are administered separately, but
2 months; 1 month; 3 weeks; 2 weeks; 1 week; 3 days; 1 day; 30. A method according to any one of claims 1 to 29, or a checkpoint inhibitor and a tdsRNA for use according to any one of claims 1 to 29, administered to.
請求項1から30のいずれかに記載の方法、または請求項1から30のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 1-5 times weekly at a dosage wherein the second compound comprising a tdsRNA administers to the subject an average of about 25-700 milligrams of tdsRNA per day for a period of up to 1 month or more , administered intravenously,
31. A method according to any of claims 1-30, or a checkpoint inhibitor and tdsRNA for use according to any of claims 1-30.
請求項1から31のいずれかに記載の方法、または請求項1から31のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 a second compound comprising a tdsRNA is administered to the subject 1-5 times weekly at a dosage that provides an average of about 25-700 milligrams of tdsRNA per day continuously for at least 1 month;
32. A checkpoint inhibitor and a tdsRNA for the method of any of claims 1-31 or the use of any of claims 1-31.
tdsRNA単独、
チェックポイント阻害剤単独、または
tdsRNA単独とチェックポイント阻害剤単独との合計
の使用を上回る相乗効果をもたらす、請求項1から32のいずれかに記載の方法、または請求項1から32のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 tdsRNA and checkpoint inhibitors together in the treatment of cancer or inhibition of tumor cell growth
tdsRNA alone,
33. The method of any of claims 1-32, or any of claims 1-32, which results in a synergistic effect over the use of checkpoint inhibitor alone, or tdsRNA alone and checkpoint inhibitor alone. Checkpoint inhibitors and tdsRNAs for the uses described.
抗体;モノクローナル抗体;ヒト化抗体;ヒト抗体;融合タンパク質;PEG化抗体;多量体抗体;エピトープ結合性領域を含む抗体断片;およびこれらの組合せ
からなる群から選択される少なくとも1つの特徴を有する、請求項1から33のいずれかに記載の方法、または請求項1から33のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 checkpoint inhibitors
humanized antibodies; fusion proteins; PEGylated antibodies; multimeric antibodies; 34. A checkpoint inhibitor and a tdsRNA for the method of any of claims 1-33, or the use of any of claims 1-33.
2B4;A2aR;B7ファミリーリガンド;B7 H3;B7 H4;BおよびTリンパ球アテニュエーター(BTLA);BMA;CD112;CD137;CD160;CD2;CD20;CD226;CD27;CD276;CD28;CD30;CD33;CD40;CD47;CD52;CD70;CD80;CD86;CGEN 15049;CHK1;CHK2;細胞傷害性Tリンパ球抗原4(CTLA-4);DR3;ガレクチン9(GAL9);GITR;ヘルペスウイルス侵入メディエーター(HVEM);ICOS;IDO1;IDO2;キラー細胞免疫グロブリン様受容体(KIR);LAG3;LAIR;LAIR1;LAIR2;LIGHT;リンパ球活性化遺伝子3(LAG-3);MARCO;OX-40;PD-1;PD-L1;PD-L2;PS;SIRPアルファ;SLAM;IgおよびITIMドメインを有するT細胞免疫受容体(TIGIT);T細胞膜タンパク質3(TIM3);Vドメイン免疫グロブリン(Ig)含有T細胞活性化サプレッサー(VISTA);VTCN1;ならびにこれらの組合せ
からなる群から選択される、チェックポイントタンパク質、チェックポイントタンパク質のリガンド、またはチェックポイントタンパク質の受容体を阻害するか、これらと相互作用するか、またはこれらに結合する、請求項1から34のいずれかに記載の方法、または請求項1から34のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 checkpoint inhibitors
B7 H3; B7 H4; B and T lymphocyte attenuator (BTLA); BMA; CD112; CD40; CD47; CD52; CD70; CD80; CD86; CGEN 15049; killer cell immunoglobulin-like receptor (KIR); LAG3; LAIR; LAIR1; LAIR2; LIGHT; lymphocyte activation gene 3 (LAG-3); PD-L1; PD-L2; PS; SIRPalpha; SLAM; T-cell immunoreceptor with Ig and ITIM domains (TIGIT); T-cell membrane protein 3 (TIM3); suppressor (VISTA); VTCN1; 35. A checkpoint inhibitor and a tdsRNA for a method according to any one of claims 1 to 34, or a use according to any one of claims 1 to 34, which binds to.
PD-1;PD-L1;細胞傷害性Tリンパ球抗原4(CTLA-4);CD80;CD86;およびこれらの組合せ
からなる群から選択される、チェックポイントタンパク質、チェックポイントタンパク質のリガンド、またはチェックポイントタンパク質の受容体を阻害するか、これらと相互作用するか、またはこれらに結合し、好ましくは、チェックポイント阻害剤が、PD-1またはPD-L1を阻害する、請求項1から35のいずれかに記載の方法、または請求項1から35のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 checkpoint inhibitors
PD-1; PD-L1; cytotoxic T lymphocyte antigen 4 (CTLA-4); CD80; CD86; 36. Any of claims 1 to 35, which inhibits, interacts with or binds to receptors of point proteins, preferably the checkpoint inhibitor inhibits PD-1 or PD-L1 A checkpoint inhibitor and a tdsRNA for a method according to any one of claims 1 to 35 or for use according to any one of claims 1-35.
アレムツズマブ;
AMP-224;
AMP-514;
アテゾリズマブ;
AUNP 12;
アベルマブ;
BMS-936559;
BMS-986016;
セミプリマブ;
CP-870,893;
CT-011;
デュルバルマブ;
ガリキシマブ;
IMP321;
INCB024360;
インドキシモド;
IPH2101;
イピリムマブ;
Libtayo;
リリルマブ;
MDX-1105;
MEDI-6469;
MGA271;
MIHI;
モガムリズマブ;
MPDL3280A;
ニボルマブ;
NLG-919;
オファツムマブ;
ペンブロリズマブ;
PF-05082566;
ピジリズマブ;
リツキシマブ;
トレメリムマブ;
ウレルマブ;
バリルマブ;および
これらの組合せ
からなる群から選択される、請求項1から38のいずれかに記載の方法、または請求項1から38のいずれかに記載の使用のためのチェックポイント阻害剤およびtdsRNA。 checkpoint inhibitors
alemtuzumab;
AMP-224;
AMP-514;
atezolizumab;
AUNP 12;
avelumab;
BMS-936559;
BMS-986016;
semiplimab;
CP-870,893;
CT-011;
durvalumab;
galiximab;
IMP321;
INCB024360;
Indoximod;
IPH2101;
ipilimumab;
Libtayo;
lililumab;
MDX-1105;
MEDI-6469;
MGA271;
MIHI;
mogamulizumab;
MPDL3280A;
nivolumab;
NLG-919;
ofatumumab;
pembrolizumab;
PF-05082566;
pygilizumab;
rituximab;
tremelimumab;
Urelumab;
39. A method according to any one of claims 1 to 38, or a checkpoint inhibitor and a tdsRNA for use according to any one of claims 1 to 38, selected from the group consisting of vallimab; and combinations thereof.
がんを、第1の化合物および第2の化合物へと、任意の順序において、併せて、または個別に曝露するか、またはこれらと接触させること
を含み、
第1の化合物が、少なくとも1つの薬学的に許容可能な担体を伴ってもよい、有効量のチェックポイント阻害剤を含み、
第2の化合物が、少なくとも1つの薬学的に許容可能な担体を伴ってもよい、有効量の治療用二本鎖RNA(tdsRNA)である、方法。 A method for treating cancer in a subject in need thereof, comprising:
exposing or contacting the cancer to a first compound and a second compound in any order, jointly or individually;
the first compound comprises an effective amount of a checkpoint inhibitor optionally associated with at least one pharmaceutically acceptable carrier;
The method wherein the second compound is an effective amount of a therapeutic double-stranded RNA (tdsRNA) optionally associated with at least one pharmaceutically acceptable carrier.
モノクローナル抗体、
ヒト化抗体、
完全ヒト抗体、
融合タンパク質、および
これらの組合せ
からなる群から選択される、請求項44から46、または請求項1から46のいずれかに記載の組成物。 checkpoint inhibitors
monoclonal antibody,
humanized antibodies,
fully human antibodies,
47. The composition of any of claims 44-46, or claims 1-46, selected from the group consisting of fusion proteins, and combinations thereof.
2B4;A2aR;B7ファミリーリガンド;B7 H3;B7 H4;BおよびTリンパ球アテニュエーター(BTLA);BMA;CD112;CD137;CD160;CD2;CD20;CD226;CD27;CD276;CD28;CD30;CD33;CD40;CD47;CD52;CD70;CD80;CD86;CGEN 15049;CHK1;CHK2;細胞傷害性Tリンパ球抗原4(CTLA-4);DR3;ガレクチン9(GAL9);GITR;ヘルペスウイルス侵入メディエーター(HVEM);ICOS;IDO1;IDO2;キラー細胞免疫グロブリン様受容体(KIR);LAG3;LAIR;LAIR1;LAIR2;LIGHT;リンパ球活性化遺伝子3(LAG-3);MARCO;OX-40;PD-1;PD-L1;PD-L2;PS;SIRPアルファ;SLAM;IgおよびITIMドメインを有するT細胞免疫受容体(TIGIT);T細胞膜タンパク質3(TIM3);Vドメイン免疫グロブリン(Ig)含有T細胞活性化サプレッサー(VISTA);VTCN1;ならびにこれらの組合せ
からなる群から選択される、チェックポイントタンパク質、チェックポイントタンパク質のリガンド、またはチェックポイントタンパク質の受容体を阻害するか、これらに結合するか、またはこれらと相互作用する、請求項44から47、または請求項1から47のいずれかに記載の組成物。 checkpoint inhibitors
B7 H3; B7 H4; B and T lymphocyte attenuator (BTLA); BMA; CD112; CD40; CD47; CD52; CD70; CD80; CD86; CGEN 15049; killer cell immunoglobulin-like receptor (KIR); LAG3; LAIR; LAIR1; LAIR2; LIGHT; lymphocyte activation gene 3 (LAG-3); PD-L1; PD-L2; PS; SIRPalpha; SLAM; T-cell immunoreceptor with Ig and ITIM domains (TIGIT); T-cell membrane protein 3 (TIM3); suppressor (VISTA); VTCN1; 48. The composition of any of claims 44-47 or claims 1-47 that interact.
PD-1;PD-L1;細胞傷害性Tリンパ球抗原4(CTLA-4);CD80;CD86;これらのリガンド;これらの受容体;およびこれらの組合せ
からなる群から選択されるチェックポイントタンパク質のリガンドを阻害するか、これらに結合するか、またはこれらと相互作用し、好ましくは、チェックポイント阻害剤が、PD-1またはPD-L1を阻害する、請求項44から48、または請求項1から48のいずれかに記載の組成物。 checkpoint inhibitors
PD-1; PD-L1; cytotoxic T lymphocyte antigen 4 (CTLA-4); CD80; CD86; ligands thereof; 44 to 48 or from claim 1, wherein the checkpoint inhibitor inhibits, binds to or interacts with a ligand, preferably inhibits PD-1 or PD-L1 48. The composition according to any of 48.
イピリムマブ;
ニボルマブ;
ペンブロリズマブ;および
これらの組合せ
からなる群から選択される、請求項44から49、または請求項1から49のいずれかに記載の組成物。 checkpoint inhibitors
ipilimumab;
nivolumab;
Pembrolizumab; and combinations thereof.
アレムツズマブ;
AMP-224;
AMP-514;
アテゾリズマブ;
AUNP 12;
アベルマブ;
BMS-936559;
BMS-986016;
セミプリマブ;
CP-870,893;
CT-011;
デュルバルマブ[IMFINZI(登録商標)];
ガリキシマブ;
IMP321;
INCB024360;
インドキシモド;
IPH2101;
イピリムマブ;
Libtayo;
リリルマブ;
MDX-1105;
MEDI-6469;
MGA271;
MIHI;
モガムリズマブ;
MPDL3280A;
ニボルマブ;
NLG-919;
オファツムマブ;
ペンブロリズマブ;
PF-05082566;
ピジリズマブ;
リツキシマブ;
トレメリムマブ;
ウレルマブ;
バリルマブ;および
これらの組合せからなる群から選択される、請求項44から49、または請求項1から50のいずれかに記載の組成物。 checkpoint inhibitors
alemtuzumab;
AMP-224;
AMP-514;
atezolizumab;
AUNP 12;
avelumab;
BMS-936559;
BMS-986016;
semiplimab;
CP-870,893;
CT-011;
durvalumab [IMFINZI®];
galiximab;
IMP321;
INCB024360;
Indoximod;
IPH2101;
ipilimumab;
Libtayo;
lililumab;
MDX-1105;
MEDI-6469;
MGA271;
MIHI;
mogamulizumab;
MPDL3280A;
nivolumab;
NLG-919;
ofatumumab;
pembrolizumab;
PF-05082566;
pygilizumab;
rituximab;
tremelimumab;
Urelumab;
and combinations thereof.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783834P | 2018-12-21 | 2018-12-21 | |
US62/783,834 | 2018-12-21 | ||
US201962792760P | 2019-01-15 | 2019-01-15 | |
US201962792765P | 2019-01-15 | 2019-01-15 | |
US62/792,760 | 2019-01-15 | ||
US62/792,765 | 2019-01-15 | ||
US201962869909P | 2019-07-02 | 2019-07-02 | |
US62/869,909 | 2019-07-02 | ||
US201962885143P | 2019-08-09 | 2019-08-09 | |
US62/885,143 | 2019-08-09 | ||
PCT/US2019/068044 WO2020132560A2 (en) | 2018-12-21 | 2019-12-20 | Compositions and methods for cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022515188A JP2022515188A (en) | 2022-02-17 |
JPWO2020132560A5 true JPWO2020132560A5 (en) | 2022-12-27 |
Family
ID=69326681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021536007A Pending JP2022515188A (en) | 2018-12-21 | 2019-12-20 | Compositions and Methods for Cancer Treatment |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220096518A1 (en) |
EP (1) | EP3897854A2 (en) |
JP (1) | JP2022515188A (en) |
KR (1) | KR20210106531A (en) |
CN (1) | CN113474048A (en) |
AU (1) | AU2019403445A1 (en) |
BR (1) | BR112021012103A2 (en) |
CA (1) | CA3124408A1 (en) |
MX (1) | MX2021007565A (en) |
NL (1) | NL2024544B1 (en) |
SG (1) | SG11202106295WA (en) |
WO (1) | WO2020132560A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11813279B2 (en) | 2018-12-21 | 2023-11-14 | Aim Immunotech Inc. | Compositions for cancer therapy and methods |
EP3999645A1 (en) * | 2020-09-21 | 2022-05-25 | Aim Immunotech Inc. | Compositions and methods for treating cancer |
CN115645515A (en) * | 2022-12-28 | 2023-01-31 | 北京圣美细胞生命科学工程研究院有限公司 | Tumor treatment composition and application, pharmaceutical composition and cell growth inhibition method |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024222A (en) | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5258369A (en) * | 1988-08-29 | 1993-11-02 | Hem Pharmaceuticals Corporation | Treatment of chronic cerebral dysfunction by dsRNA methodology |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
DK2206517T3 (en) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
CA2855098C (en) | 2007-06-18 | 2018-02-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
PT2231628E (en) * | 2008-01-04 | 2015-12-29 | Gilead Sciences Inc | Inhibitors of cytochrome p450 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
US8722874B2 (en) | 2008-10-23 | 2014-05-13 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
US20100160413A1 (en) | 2008-10-23 | 2010-06-24 | Hemispherx Biopharma, Inc. | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
US20140170191A1 (en) * | 2008-10-23 | 2014-06-19 | Hemispher Biopharma, Inc. | Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
PL2340307T3 (en) * | 2008-10-23 | 2016-02-29 | Hemispherx Biopharma Inc | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US9096642B2 (en) | 2011-06-08 | 2015-08-04 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
CA3139031A1 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
AR093984A1 (en) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN |
HUE049281T2 (en) | 2013-09-13 | 2020-09-28 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
BG111827A (en) | 2014-09-24 | 2016-03-31 | Динко Бахов | METHOD AND DEVICE FOR SUSPENSION OF STEEL FIBER |
JP2018507884A (en) | 2015-03-10 | 2018-03-22 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
US10781189B2 (en) | 2015-03-10 | 2020-09-22 | Aurigene Discovery Technologies Limited | 1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators |
CA2979161A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
WO2016142852A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
WO2016142835A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | Therapeutic cyclic compounds as immunomodulators |
-
2019
- 2019-12-20 SG SG11202106295WA patent/SG11202106295WA/en unknown
- 2019-12-20 NL NL2024544A patent/NL2024544B1/en active
- 2019-12-20 MX MX2021007565A patent/MX2021007565A/en unknown
- 2019-12-20 CA CA3124408A patent/CA3124408A1/en active Pending
- 2019-12-20 BR BR112021012103-0A patent/BR112021012103A2/en unknown
- 2019-12-20 WO PCT/US2019/068044 patent/WO2020132560A2/en unknown
- 2019-12-20 JP JP2021536007A patent/JP2022515188A/en active Pending
- 2019-12-20 US US17/416,358 patent/US20220096518A1/en active Pending
- 2019-12-20 KR KR1020217022967A patent/KR20210106531A/en unknown
- 2019-12-20 EP EP19842974.8A patent/EP3897854A2/en active Pending
- 2019-12-20 AU AU2019403445A patent/AU2019403445A1/en active Pending
- 2019-12-20 CN CN201980092816.2A patent/CN113474048A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200138804A1 (en) | Methods for treating cancer | |
KR20190053909A (en) | Combination therapy of antibodies and checkpoint immunosuppressants | |
US20210047425A1 (en) | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells | |
CA3103635A1 (en) | Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition antibody-mediated target cytosis | |
KR20200029543A (en) | Receptor subtypes and functional selective retinoids and rexinoid compounds combined with immunomodulators for cancer immunotherapy | |
NL2024544B1 (en) | Compositions And Methods For Cancer Therapy | |
JPWO2020132560A5 (en) | ||
KR20220016156A (en) | Polyoncogene signatures for suitability for immuno-oncology therapy | |
US20240052061A1 (en) | Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3 | |
US20210196744A1 (en) | Compositions for cancer therapy and methods | |
US20220280609A1 (en) | Combination cancer therapy agents and methods | |
US20220288124A1 (en) | Car-t cell compositions, methods of use thereof | |
KR20220016155A (en) | Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy | |
US20240000883A1 (en) | Method of sensitizing cancers to immunotherapy using immunomodulatory agents | |
US20220233691A1 (en) | Cell localization signature and combination therapy | |
US20220259669A1 (en) | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy | |
WO2023168404A1 (en) | Methods of treating a tumor | |
WO2021009761A1 (en) | Combination therapy for the treatment of cancer | |
AU2020285473A1 (en) | Methods for modulating T cell activation |